Philips has reported an increase in group sales in the second quarter (Q2) of 2021 to $4.95bn (€4.2bn), signifying a 9% comparable sales growth as against last year.
For the quarter, net income stood at approximately $177m (€153m).
Go deeper with GlobalData
Adjusted EBITA margin rose to nearly $627m (€532m), a surge of 12.6% in the quarter as against $424m (€390m) or 9.8% of sales in the second quarter last year.
Operating cash flow in the second quarter of 2021 was $391m (€332m) as against $557m (€446m) in Q2 2020, while the free cash flow stood at $197m (€167m) versus $250m (€212m) last year.
Comparable order intake witnessed a 15% decline during the quarter with robust double-digit growth in the Diagnosis and Treatment businesses.
The Diagnosis and Treatment businesses generated 16% comparable sales growth and saw a 29% rise in comparable order intake, with double-digit growth in image-guided therapy, ultrasound and diagnostic imaging.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataA 16% decline in comparable sales in the Connected Care businesses was seen in Q2 2021.
A mid-single-digit growth in Hospital Patient Monitoring was balanced by a double-digit decline in Sleep and Respiratory Care.
Philips noted that the comparable order intake dropped significantly in the second quarter of 2021 due to the steep Covid-19-linked growth in Q2 last year.
The recently acquired BioTelemetry and Capsule Technologies businesses delivered robust sales growth with growing profitability.
In the Personal Health businesses, a 33% comparable sales growth was noted in the quarter which was caused by double-digit growth in all businesses.
Philips CEO Frans van Houten said: “I am pleased with the good performance momentum in all our businesses except the Sleep and Respiratory Care business, as we delivered a strong 9% comparable sales growth and 280 basis points profitability improvement for the group in the quarter.
“I am particularly encouraged by the 29% order intake growth in our Diagnosis and Treatment businesses, as well as the strong growth of our Personal Health businesses.”
Furthermore, Philips announced a share buyback programme, for capital reduction purposes, totalling up to $1.7bn (€1.5bn).
The company anticipates commencing the programme in the third quarter of this year, with plans to conclude it in three years.
In other news, Philips initiated a voluntary recall of some Sleep and Respiratory care products last month.
